Researchers have performed a comprehensive evaluation of five artificial intelligence (AI) models trained on genomic sequences, known as DNA language models. These comparisons provide valuable insights into their strengths and weaknesses and offer a framework for selecting appropriate models based on specific genomic tasks. The study was led by Chong Wu, Ph.D., assistant professor of Biostatistics and affiliate of the Institute for Data Science in Oncology; and Peng Wei, Ph.D., professor of Biostatistics. Post Views: 205

Patients with lower-risk myelodysplastic syndromes (MDS) experienced strong responses with fewer side effects when treated with a five-day azacitidine compared to shorter durations of azacitidine or decitabine. Final data from the trial was presented by Ian Bouligny, M.D., assistant professor of Leukemia.   “For patients with lower-risk MDS, a five-day duration of azacitidine was safe and effective, showing improved event-free survival and overall survival compared to three-day durations of azacitidine or decitabine,” Bouligny said. “We’ve seen firsthand how this approach improves...

Researchers have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression of the CD40 protein as a potential biomarker associated with improved overall survival (OS). The study was led by Francisco Vega, M.D., Ph.D., professor of Hematopathology, and Tania Sainz, graduate research assistant.   “The discovery of CD40 overexpression as a potential biomarker gives us a new lens to assess patient risk and opens the door to therapeutic...

In a Phase Ib/II trial led by Naval Daver, M.D., professor of Leukemia, patients with newly diagnosed CD123-positive acute myeloid leukemia (AML) who were unable to undergo intensive chemotherapy had strong response rates from the triplet combination of venetoclax, azacitidine and pivekimab sunirine (PVEK).   “This triplet regimen may represent a significant step forward for older patients with CD123-positive AML who are not candidates for intensive chemotherapy,” Daver said. “The remission and MRD rates we observed are very encouraging...